Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
25 April 2023 - 6:05AM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
the appointment of Roger Dansey, M.D., to the company’s Board of
Directors. Dr. Dansey brings extensive experience in oncology drug
development and a proven track record in the biotechnology
industry. He currently serves as president, research and
development of Seagen Inc.
“Roger is an experienced leader in cancer drug
development, and we are proud to welcome him to our Board,” said
Norbert Bischofberger, Ph.D., president and chief executive officer
of Kronos Bio. “Roger’s deep understanding of the clinical research
landscape makes him an exceptional addition to the team. We look
forward to his guidance and expertise as we work to develop our
portfolio of product candidates that target dysregulated
transcription.”
“Kronos Bio’s differentiated approach to targeting
transcription factors positions it well to discover, develop and
deliver medicines for difficult to treat cancers,” said Dr. Dansey.
“This is a pivotal time for Kronos Bio and I look forward to
working with this talented board and leadership team to achieve
these goals and further advance the company’s robust pipeline.”
Dr. Dansey has dedicated his career to the
development of innovative cancer therapies. Prior to joining
Seagen, Dr. Dansey held senior leadership roles at Merck, Gilead
Sciences and Amgen. Dr. Dansey holds an M.D. from the University of
Witwatersrand in Johannesburg, South Africa. He serves as a member
of the board of directors for INOVIO Pharmaceuticals, Inc.
About Kronos Bio, Inc.Kronos Bio
is a biopharmaceutical company that is advancing two
investigational compounds in clinical trials for patients with
cancer. The company is developing the CDK9 inhibitor KB-0742 as a
treatment for MYC-amplified solid tumors and other
transcriptionally addicted solid tumors and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The company’s scientific focus is on developing
medicines that target the dysregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a
research facility in Cambridge, Mass. For more information, visit
www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Sarah
ConnorsKronos Biosconnors@kronosbio.com857-290-7305
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Media: Leo Vartorella/David
RosenArgot Partners212-600-1494kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Apr 2024 to May 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From May 2023 to May 2024